GLP-1 drugs linked to major drop in pancreatic, colorectal cancer risk
11 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"GLP-1 drugs linked to major drop in pancreatic, colorectal cancer risk" is generating significant coverage in the Health category, with 11 articles from 11 distinct sources tracked by PULSE so far.
Outlets currently covering the story include MindBodyGreen, KATV, Endocrinology Advisor and Discover Magazine. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 151d ago.
Quick answers
Why is "GLP-1 drugs linked to major drop in pancreatic, colorectal cancer risk" trending?
Because 11 independent news sources published 11 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (11)
- GLP-1s May Lower The Risk Of These 13 Cancers, New Study Finds MindBodyGreen · 154d ago
- Study: GLP-1 weight loss drugs tied to 30% lower breast cancer risk in women KATV · 154d ago
- GLP-1 Receptor Agonist Use Linked to Lower Incidence of Obesity-Associated Cancers Endocrinology Advisor · 154d ago
- Weight Loss Drugs Like Ozempic May Lower Breast Cancer Risk and Slow Disease Progression Discover Magazine · 154d ago
- Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer AJMC · 154d ago
- GLP-1 drugs linked to reduced cancer risk, researchers say WPTV · 154d ago
- GLP-1s Tied to Lower Cancer Risk in Patients With Obesity Medscape · 154d ago
- Doctors Say These Drugs May Reduce Cancer Risk 59% More Than Diet and Exercise Prevention · 154d ago
- New study: Possible link between weight-loss drugs and slowing cancer spread The Jerusalem Post · 154d ago
- Penn Med study finds GLP-1 use may lower breast cancer incidence The Daily Pennsylvanian · 154d ago
- Breast Imaging in Focus: Can GLP-1 Receptor Agonists Reduce Breast Cancer Risk? What New Research Reveals diagnosticimaging.com · 154d ago
Topics
Related trends
GLP-1 poison calls surge in Georgia as experts warn about unapproved weight-loss drugs - WSB-TV
Georgia poison centers report a surge in calls linked to GLP-1 weight-loss drugs as experts flag risks from unapproved versions.
Should you take GLP-1s during pregnancy? What some doctors say.
New research on GLP-1 drugs during pregnancy sparks urgent debate among doctors and patients.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.